MCK Earnings Date: Nov 4, 2026 — McKesson Corporation
NYSE · Healthcare · Medical Distribution
Updated
When is MCK's next earnings date?
McKesson Corporation (MCK) is scheduled to report Q2 2027 earnings on Wednesday, November 4, 2026 at 4:10 PM ET (after market close). The consensus estimate is EPS of $10.72 on revenue of $109.90B.
How did MCK do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q1 2027), McKesson Corporation posted EPS of $9.93 versus the $9.56 estimate, a beat of 3.2%. Revenue was $105.38B against a $103.88B estimate. The stock's 1-day post-earnings move was -0.7%.
How much does MCK stock move after earnings?
MCK beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.9% (up or down) in the day after earnings.
About McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q1 2027 | 9.56 | 9.93 | +3.22% | $105.38B | ✅ Beat | -0.67% | +0.17% | +5.14% |
| 2026-05-07 | Q4 2026 | 11.57 | 11.69 | +1.04% | $96.30B | ✅ Beat | -2.47% | -1.00% | +1.69% |
| 2026-02-04 | Q3 2026 | 9.29 | 9.34 | +0.54% | $106.16B | ✅ Beat | +16.52% | +15.96% | +11.93% |
| 2025-11-05 | Q2 2026 | 9.00 | 9.86 | +9.56% | $103.15B | ✅ Beat | +1.70% | -0.42% | -4.13% |
| 2025-08-06 | Q1 2026 | 8.18 | 8.26 | +0.98% | $97.83B | ✅ Beat | -5.76% | -5.77% | -2.21% |
| 2025-05-08 | Q4 2025 | 9.83 | 10.12 | +2.95% | $90.82B | ✅ Beat | +0.47% | +2.39% | +2.71% |
| 2025-02-05 | Q3 2025 | 7.99 | 8.03 | +0.50% | $95.29B | ✅ Beat | -1.18% | -1.96% | +6.27% |
| 2024-11-06 | Q2 2025 | 6.88 | 7.07 | +2.76% | $93.65B | ✅ Beat | +10.60% | +13.71% | +10.00% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q1 FY27 · $105.38B total
| Segment | Share | Revenue | YoY | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| North American Pharmaceutical | 82.3% | $86.77B | — | — | — | — | $86.48B |
| Oncology And Multispecialty | 13.5% | $14.22B | — | — | — | — | $12.04B |
| Medical-Surgical Solutions | 2.7% | $2.82B | +4.4% | $2.95B | $2.85B | $2.70B | $2.95B |
| Prescription Technology Solutions | 1.5% | $1.57B | +9.2% | $1.37B | $1.34B | $1.43B | $1.38B |
By region
Q1 FY21 · $55.68B total
| Segment | Share | Revenue | YoY | Q3 FY19 | Q4 FY19 | Q1 FY20 | Q2 FY20 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 84.6% | $47.13B | +1.7% | $46.52B | $43.11B | $46.32B | $48.29B |
| International | 15.4% | $8.55B | -9.1% | $9.69B | $9.32B | $9.41B | $9.32B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.